Termination of early pregnancy by vacuum aspiration Pregnancy and Childbirth Termination
Conditions
Interventions
Two tablets of 200 micrograms of misoprostol or two placebo tablets will be administered vaginally three hours before vacuum aspiration. Type of analgesia/anaesthesia, baseline cervical dilation, dura
Sponsors
UNDP/UNFPA/WHO/World Bank - Special Programme of Research, Development and Research Training in Human Reproduction
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Women requesting abortion and eligible for legal termination of normal single intrauterine pregnancy of less than 12 completed weeks (84 days) of gestation 2. Consent to participation 3. Able to understand information on the study 4. Agree to return for the scheduled follow-up visit
Exclusion criteria
Exclusion criteria: Women are not eligible if they have: 1. A medical condition or disease that requires special treatment, care of precautions in conjunction with vacuum aspiration 2. Allergy to misoprostol 3. Contraindications to misoprostol 4. Anaemia or any coagulation disorder
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complication rates in misoprostol and placebo groups, measured during the procedure, in the immediate post-operative period, and up until the follow-up visit 7 to 14 days after the procedure | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Ease of the procedure (dilation, duration of procedure, pain level), measured during the procedure 2. Side-effects, measured at any time after administration of misoprostol until the end of the study | — |
Countries
Armenia, China, Cuba, Hungary, India, Mongolia, Romania, Slovenia, Viet Nam
Outcome results
None listed